Business
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
HYOGO, Japan, September 30, 2025--JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT 32nd Annual Congress.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/936e1c55b80e18b530782e802d4ad7d7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YC3YCGMIFPl5XLtgg687AQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/936e1c55b80e18b530782e802d4ad7d7","width":480,"height":251}},"lazy":false},{"type":"text","content":"HYOGO, Japan, September 30, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress, being held October 7-10, 2025, in Seville, Spain.","length":479,"tagName":"p"},{"type":"text","content":"JUST-AAV encompasses a range of vector types optimized for various target tissues, including liver-sparing, muscle-targeting, and brain-targeting variants. Its target specificity is enhanced via a new muscle-targeting binder that shows cross-species affinity and improved muscle transduction when incorporated into an adeno-associated virus (AAV) capsid, compared to AAV9. JUST-AAV thus holds significant promise for advancing the field of AAV-based gene therapy.","length":463,"tagName":"p"},{"type":"text","content":"The oral presentation details are listed below, and the full program can be found on the ESGCT congress website at www.esgctcongress.com.","length":137,"tagName":"p"},{"type":"text","content":"Title: Generation of a novel capsid engineering platform enhances CNS and muscle tropism of AAV vectors while reducing tropism to the liverOral Presentation Number: OR009Date: October 7, 2025, 5:00-7:30pm CESTPresenter: Shunsuke Iizuka, Ph.D., JCR Pharmaceuticals","length":266,"tagName":"p"},{"type":"text","content":"About the European Society of Gene and Cell Therapy (ESGCT)Established in 1992, the European Society of Gene and Cell Therapy (ESGCT) seeks to support scientists and clinicians working in the fields of gene and cell therapy and to promote awareness and understanding of gene and cell therapy and th...